Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of products that treat several neurological diseases as well as other conditions. The company’s pipeline provides opportunity for further growth. Check out this report to see the biopharma company’s most recent quarterly performance as well as its growth opportunities.
Table of Contents
- Overview
- Financial Highlights
- Outlook
- SWOT Analysis
- Business Segment Analysis
- Strategic Drivers